Paul Sandland

Paul Sandland's Title

Paul Sandland holds the prominent position of Chief Financial Officer at Dechra Pharmaceuticals. His role encompasses overseeing all financial operations, strategic planning, and ensuring the financial health of the company. As CFO, he is integral to the executive team, contributing to key decisions and guiding the company towards sustainable growth.

Paul Sandland's Company

Paul Sandland is a pivotal figure at Dechra Pharmaceuticals, a leading global specialist in veterinary pharmaceuticals and related products. Since joining the company in January 2010, he has held various significant roles, culminating in his appointment as Chief Financial Officer in October 2019. His leadership has been instrumental in driving the company's financial strategy and operational success.

Paul Sandland's Education and Expertise

Paul Sandland is a Chartered Certified Accountant, a qualification that underscores his strong technical foundation and financial acumen. His expertise spans strategic planning, commercial skills, and technical knowledge, all of which are crucial in his role as CFO. His background with KPMG, where he spent five years post-qualification, provided him with a robust understanding of financial advisory and auditing, further enhancing his capabilities.

Paul Sandland's Background

Paul Sandland's professional journey began at KPMG, where he spent five years post-qualification honing his skills in financial advisory. Notably, he was part of the team advising on the acquisition of VetXX in 2008, showcasing his early involvement in significant financial transactions. He joined Dechra as the Group Financial Controller in January 2010, steadily climbing the ranks to become an Executive Director and CFO by October 2019. His background is marked by a blend of technical proficiency and strategic insight, making him a key asset to Dechra.

Paul Sandland's Achievements

Among Paul Sandland's notable achievements is his role in advising on the acquisition of VetXX in 2008, a significant milestone in his career. His appointment as CFO of Dechra Pharmaceuticals in 2019 is another testament to his capabilities and leadership. As a Board Director responsible for Health and Safety and ESG matters, Paul has demonstrated a commitment to sustainable practices and corporate governance, further solidifying his reputation as a forward-thinking executive.